TSE:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis C$1.51 +0.01 (+0.67%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock About Cardiol Therapeutics Stock (TSE:CRDL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cardiol Therapeutics alerts:Sign Up Key Stats Today's RangeC$1.47▼C$1.5750-Day RangeC$1.40▼C$2.1052-Week RangeC$1.09▼C$3.28Volume154,903 shsAverage Volume98,887 shsMarket CapitalizationC$126.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. Read More Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRDL Stock News HeadlinesCardiol Therapeutics (TSE:CRDL) Shares Up 3.4% - What's Next?September 11, 2025 | americanbankingnews.comCardiol falls after mid-stage data for heart disease treatmentAugust 6, 2025 | msn.comCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really investing in this coin.September 18 at 2:00 AM | Crypto 101 Media (Ad)Cardiol Therapeutics Inc. (CRDL.TO) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comStocks in play: ardiol Therapeutics Inc.April 17, 2025 | ca.finance.yahoo.comCardiol Therapeutics reports heart failure treatment progressFebruary 21, 2025 | investing.comVernon Bernardino Issues Buy Rating on Cardiol Therapeutics Following Promising Clinical Results and Strong Financial PositionDecember 19, 2024 | markets.businessinsider.comCBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical StudyNovember 19, 2024 | benzinga.comSee More Headlines CRDL Stock Analysis - Frequently Asked Questions How have CRDL shares performed this year? Cardiol Therapeutics' stock was trading at C$1.85 at the start of the year. Since then, CRDL shares have decreased by 18.4% and is now trading at C$1.51. How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Cardiol Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include Cardiol Therapeutics (CRTPF), Rolls-Royce Holdings plc (RR.L), Very Good Food (VRYYF), Gilead Sciences (GILD), Impel Pharmaceuticals (IMPL), Luminar Technologies (LAZR) and Meta Platforms (META). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolTSE:CRDL CIKN/A Webwww.cardiolrx.com Phone289 910 0850FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$42.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-195.07% Return on Assets-54.15% Debt Debt-to-Equity Ratio1.59 Current Ratio2.49 Quick Ratio6.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$1.54 per share Price / Cash Flow0.98 Book ValueC$0.15 per share Price / Book10.11Miscellaneous Outstanding Shares83,729,000Free FloatN/AMarket CapC$126.43 million OptionableNot Optionable Beta0.95 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (TSE:CRDL) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.